Frequently asked questions
These are some of the most commonly asked questions about genetic testing and counselling.
Search
Search results
Meet a Researcher: Dr Jenny Dewing
Jenny Dewing is a postdoctoral researcher working on a Retina UK-funded project with Dr Arjuna Ratnayaka at the University of Southampton.
Diagnosis and beyond
Making yourself aware of the what you are entitled to, and understanding the diagnosis pathway for inherited sight loss, will put you in a stronger position to seek better support.
Disability sector calling for cost of living support
Retina UK has joined with more than 80 disability charities who have today written to the Chancellor calling for urgent support with the cost of living for disabled people.
e-Newsletter – January 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Remember Retina UK in your Will
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
Meet our community: Mark Baxter
My name is Mark Baxter and from an early age I was diagnosed with a deteriorating retinal eye condition called retinitis pigmentosa or RP for short, which will slowly lead to blindness.
Information for employers
If you are considering employing someone with inherited sight loss, or have an employee recently been diagnosed with the condition, you will need to take steps to ensure that you treat them fairly and that they can work safely and effectively.
Information for teachers
If you have a child with a visual impairment joining your class, you may have questions about how best you can teach and help them.
FAQs: Luxturna (voretigene neparvovec)
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.